U.S. stock market midday update: Recursion Pharmaceuticals up 9.35%, executives increase holdings and new cooperation agreement boosts confidence

U.S. Stock Market Midday Update Recursion rose 9.35%. Based on recent key news: On November 19, executives Khan Najat and Taylor Ben R of Recursion Pharmaceuticals submitted Form 4 to the SEC, disclosing changes in shareholdings. Both executives returned some shares to the company to cover option exercise costs and tax liabilities. This news may be interpreted by the market as internal confidence in the company's future development, driving the stock price up. On November 18, Recursion Pharmaceuticals announced a new collaboration agreement aimed at accelerating its drug development process. The completion of this agreement is seen as an important strategic advancement for the company, enhancing investor expectations for future growth and further driving the stock price up. On November 17, overall optimism in the biotechnology sector increased, with investors recognizing Recursion Pharmaceuticals' innovative capabilities, leading to a significant rise in stock price. The biotechnology sector has performed strongly recently, with noticeable capital inflows. Stocks with High Trading Volume in the Industry Precision Science rose 0.32%. Based on recent key news: On November 20, Abbott announced the acquisition of Precision Science for $105 per share, with a total transaction value of approximately $21 billion. This news drove Precision Science's stock price up by 18%. Source: Barron's On November 20, Precision Science's stock price rose 21% to about $84 due to acquisition rumors from Abbott. Analysts believe the acquisition valuation needs to reach 6 to 7 times future sales. Source: Zhitong Finance On November 21, Barclays and Wells Fargo raised the target price for Precision Science to $105, reflecting the market's positive expectations for the acquisition. Source: FactSet The cancer diagnostics market is growing rapidly, with noticeable capital inflows. AbbVie rose 3.52%. Based on recent key news: On November 19, AbbVie's Epkinly received FDA approval for the treatment of relapsed or refractory follicular lymphoma, expanding its indications. This approval may enhance market confidence in AbbVie, driving the stock price up. On November 21, analyst ratings show AbbVie is currently rated as "Moderate Buy," but it is not included in the top recommended stocks list. Nevertheless, the market remains optimistic about its future performance, supporting the rise in stock price. On November 19, AbbVie announced that its drug Rinvoq received FDA approval for a new indication for the treatment of inflammatory bowel disease. This news may further boost investor confidence in the company's product line, promoting an increase in stock price. Innovation in the pharmaceutical industry drives stock price increases. Gilead Sciences rose 2.25%. Based on recent key news: On November 19, Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences, and Johanna Mercier, Chief Business Officer, reported the sale of the company's common stock. These insider transactions may raise market concerns about the confidence of the company's management, leading to stock price fluctuations. On November 19, Gilead Sciences announced that Deborah H. Telman will resign from her position as Executive Vice President on December 5. This executive change may affect investors' expectations regarding the company's future strategy, thereby impacting the stock price. On November 19, analysts held a positive attitude towards Gilead Sciences' technical indicators, despite potential overbought conditions. Support from technical indicators may drive the stock price up. The biopharmaceutical industry has shown strong performance recently, with significant capital inflows. Stocks Ranked Among the Top by Market Capitalization in the Industry Amgen rose by 2.39%. Based on recent key news: On November 19, the U.S. FDA officially approved Amgen's Imdelltra for the treatment of extensive-stage small cell lung cancer. The drug showed significant survival extension effects in clinical trials, driving the stock price up. Source: Reuters On November 20, Amgen Vice President Grygiel Nancy A submitted an application to sell restricted stock involving 3,139 shares. This move may attract market attention regarding the company's internal developments. Source: SEC announcement On November 21, analyst Mizuho Securities maintained a hold rating on Amgen, setting a target price of $280. The stability of analyst ratings may provide support for the stock price. Source: TipRanks The biopharmaceutical industry's innovation is accelerating, but risks should be monitored